跳至主要内容
临床试验/NL-OMON54426
NL-OMON54426已完成不适用

Cryoablation for Monomorphic Ventricular Tachycardia - CryoCure VT

Adagio Medical0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • IC 1 Male or female the ages of >= 18 years
  • IC 2 Eligible for a catheter ablation due to Ischemic and/or non-ischemic
  • recurrent symptomatic sustained monomorphic Ventricular Tachycardia also
  • defined as having a similar QRS configuration from beat to beat.
  • IC 3 Has or will be receiving an ICD prior to hospital discharge post procedure.
  • IC 4 Refractory to at least one AAD (Refractory is defined as an AAD not able
  • to treat the arrhythmia satisfactorily or induces unwanted side effects).
  • IC 5 Subject has LVEF > 20%, confirmed by echo or comparable technique in the
  • previous 3 months or during baseline evaluation
  • IC 6 Willingness, ability, and commitment to participate in baseline and
  • follow-up evaluations for the full length of the study
  • IC 7 Willingness and ability to give an informed consent

排除标准

  • EC 1 Any known objective contraindication to ventricular tachycardia ablation,
  • TEE, or anticoagulation, including but not limited to the identification of any
  • cardiac thrombus or evidence of sepsis
  • EC 2 Any duration of continuous arrythmia that is not monomorphic ventricular
  • tachycardia. Multiple monomorphic tachycardia is acceptable, but polymorphic VT
  • EC 3 Any VT ablation within 4 weeks prior to enrollment
  • EC 4 More than one prior (>4 weeks) Ventricular Tachycardia ablation or prior
  • surgical treatment for ventricular tachycardia
  • EC 5 Ventricular tachycardia secondary to electrolyte imbalance, active thyroid
  • disease, or any other reversible or non-cardiac cause
  • EC 6 Structural heart disease as described below:
  • a. Class IV heart failure
  • b. Aortic aneurysm
  • c. Previous cardiac surgery or percutaneous coronary intervention within 60
  • days prior to the procedure
  • d. Interatrial baffle, closure device, patch, or PFO occlusion device
  • e. IVC filter
  • f. Coronary artery bypass graft (CABG) procedure within six (6) months prior
  • to the ablation procedure
  • g. Severe Mitral or Aortic insufficiency or stenosis based on most recent TTE
  • h. Cardiac myxoma
  • i. Significant congenital anomaly
  • j. Recent Myocardial Infarct (MI) or unstable angina, within 60 days prior to
  • the ablation procedure
  • k. Mechanical aortic or mitral valve
  • EC 7 Any previous history of cryoglobulinemia
  • EC 8 History of blood clotting or bleeding disease
  • EC 9 Any prior history of documented cerebral vascular accident (CVA), TIA or
  • systemic embolism (excluding a post-operative Deep Vein Thrombosis, DVT),
  • within 6 months prior to the ablation procedure.
  • EC 10 Breastfeeding, pregnant, or anticipated pregnancy during study follow-up
  • EC 11 Current enrollment in any other study protocol where testing or results
  • from that study may interfere with the procedure or outcome measurements for
  • EC 12 Any other condition that, in the judgment of the investigator, makes the
  • patient a poor candidate for this procedure, the study or compliance with the
  • protocol (includes vulnerable patient population, mental illness, addictive
  • disease, candidate for heart transplantation, patient with ventricular assist
  • device, or terminal illness with a life expectancy less than 12 months)

研究者

发起方
Adagio Medical

相似试验

Cryoablation for Monomorphic Ventricular Tachycardia | 临床试验